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Abstract: Background and Objectives: Tumours are often low immunogenic. The role of complement,
an innate immune defence system, in tumour control has begun to be elucidated, but findings
are conflicting. A role for properdin, an amplifier of complement activation, in tumour control
has recently been implicated. Materials and Methods: Properdin-deficient and congenic wildtype
mice were injected subcutaneously with B16F10 melanoma cells. Tumour mass and chemokine
profile were assessed. The frequencies of CD45+CD11b+ Gr-1+ cells were determined from tumours
and spleens, and CD206+ F4/80+ cells were evaluated in spleens. Sera were analysed for C5a,
sC5b-9, and CCL2. Results: Whilst there was no difference in tumour growth at study endpoint,
properdin-deficient mice had significantly fewer myeloid-derived suppressor cells (MDSCs) in their
tumours and spleens. Splenic M2 type macrophages and serum levels of C5a, sC5b-9, and CCL2 were
decreased in properdin-deficient compared to wildtype mice. Conclusions: The presence of intact
complement amplification sustains an environment that lessens potential anti-tumour responses.
Keywords: CCL2; MDSC; melanoma; B16
1. Introduction
Mouse models of various tumours have been employed as preclinical models to inform
or direct management of human disease, though they have their limitations [1]. Syngeneic
tumour models involve implantation of tumour cells of the same genetic background as the
host and therefore mimic the human situation when tumours arise in an immunocompetent
host after having escaped immune recognition [2]. B16 melanoma models are poorly
immunogenic [3]. In comparison to highly immunogenic solid tumour models, B16-
induced tumours show relatively greater expansion and a paucity in expression of genes
characteristic of activated T cells and dendritic cells. Immune suppressive cell populations
(regulatory T cells and myeloid-derived suppressor cells (MDSCs)) are detectable in tumour
as well as spleen and associate with a poor response to experimental immunotherapy [4].
The mouse spleen is able to receive progenitor cells from bone marrow (in the adult) and,
unlike human, provides a suitable niche for hematopoietic differentiation [5], from where
they may seed target tissues including tumours [6]. Monocytic replenishment from spleen
in a mouse model of lung adenocarcinoma was CCR2 dependent and impacted on tumour
growth [7].
Recent studies have highlighted the importance of innate immune pathways in mod-
ulating the tumour microenvironment. Specifically, complement anaphylatoxins lead to
activation, movement, and proliferation of cells. C5a and C3a bind to MDSCs, tumour
infiltrating lymphocytes, and tumour cells, and thereby dampen adaptive immunity and
consequently increase metastatic potential [8]. In a syngeneic model of cervical cancer,
primary tumours in the flanks showed C3 dependent tumour growth, activation of the
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classical pathway of complement, and C5a mediated recruitment of CD45+ CD11b+hi Gr1+
MDSC into tumours [9].
B16F10 is a melanoma cell line which is injected subcutaneously and allows investiga-
tion of an orthotopic tumour (in the skin). A 14-day model of B16F10 melanoma growth
using wildtype and C3−/− mice showed that smaller tumour development was associated
with greater IL-10 expression in C3−/− CD8+ T cells, which were increased, while the
numbers of CD45+ CD11b+ Gr1+ tumour infiltrating leukocytes remained comparable [10].
Similarly, a C3aR-positive host environment was found to benefit tumour growth
in another 14-day model of B16F10 melanoma comparing wildtype and C3aR−/− mice.
C3aR−/− mice showed a change in the proportions of different leukocyte subpopulations in
tumour infiltrates and had increased CCL5 in lysates from tumours. Daily intraperitoneal
injections with C5aR or C3aR antagonists of tumour-bearing mice led to a significant reduc-
tion in the tumour mass compared to the vehicle controls [11]. In contrast, a dependence
on C3 or C5 could not be demonstrated in a different study of B16F10 melanoma growth
over 14 days but showed a significant contribution of C1q to tumour development [12].
These differences may point to differences in cell culture conditions or in a subline that has
evolved, particularly as metastatic potential was evaluated in the latter but not the two
former studies.
Properdin is a positive regulator of the alternative pathway of complement activation
that stabilises the alternative pathway convertases which generate C3a and C5a. We have
previously studied the in vitro effect of B16F10 conditioned medium on the profile of bone
marrow-derived macrophages of properdin-deficient and wildtype mice. We found that
macrophages from properdin-deficient mice were skewed towards an M2 phenotype and
speculated that “properdin insufficiency may promote a tumour environment that helps
the tumour evade the immune response” [13].
Our aim was to determine whether properdin is an important modulator of tumour
growth in vivo. We found that while overall tumour growth was not significantly impacted
by the absence of properdin, there was significantly less CCL2 chemokine and fewer Gr1+
CD11b+ MDSCs as well as M2 type macrophages compared with wildtype counterparts.
2. Materials and Methods
2.1. Mice
All animal experiments were carried out after acquiring approval from the institutional
ethical review committee (University of Leicester) and conducted in accordance with United
Kingdom Home Office regulations (project license PPL 80/2354—approved 1 December
2014). The severity of the protocol used in this paper was classed as moderate. Age-matched
male congenic mice were taken from the properdin-deficient mouse colony held at the
University of Leicester [14]. Wildtype and properdin-deficient mice were subcutaneously
injected with tumour cell suspensions in their flanks and monitored for their wellbeing
and tumour growth every other day to daily. Some received an additional injection of
luciferin where indicated (imaging). Mice reached their endpoint (tumour size: 1 cm in one
dimension) within 14 days.
2.2. Cells
Mouse melanoma cells B16F10 were grown as described [13] and extensively washed
in phosphate buffered saline (PBS) prior to injection at 1.6 × 105 cells/100 µL. B16F10-luc
cells (mouse melanoma cells expressing luciferase) were kindly provided by Dr. Victoria
Brentville (Scancell, Nottingham, UK) and injected at a dose of 4 × 105 cells/100 µL.
Cells were confirmed to be mycoplasma negative using the EZ-PCR Mycoplasma Test Kit
(Biological Industries, Cromwell, CT, USA).
2.3. Determination of Tumour Mass, Bioimaging
Callipers were used to measure baseline tumour width and length (mm3). The fol-
lowing formula was used to calculate tumour volume because of the ellipsoid shape of
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the tumour mass: 0.5 × A × B2, where A and B are the diameters in mm. In other groups,
tumours were weighed after removal at necropsy. Bioluminescence was used in others.
To do this, mice which had received B16F10-luc cells were injected in the scruff of their
neck with 150 µg/kg luciferin subcutaneously and their tumours were imaged using IVIS®
Spectrum In Vivo Imaging System (Caliper Life Sciences, Hopkinton, MA, USA) a pilot
experiment to discern distribution kinetics of luciferin. Light emission was measured under
anaesthesia with recovery 10 min after substrate injection.
2.4. Proteome Array Analysis
Tumour lysates were prepared and membranes (Proteome Profiler™ Array; R&D
Systems, Abingdon, UK) were hybridised with 300 µg total protein. Pixel densities on
developed X-ray film were analysed using a transmission mode scanner and image analysis
software. A template was created to analyse the pixel density of each spot on the array. Then
signal values were exported to an Excel (Microsoft Excel 2013) spreadsheet for analysis. The
average signal of the pair of duplicate spots representing each cytokine was determined.
The signal from a clear area of the array or negative control spots was used as a background
value, and the background signal was subtracted from each spot.
2.5. ELISA
ELISA sandwich assays were used to detect C5a (R&D Systems, DY2150), CCL2
(Affymetrix eBioscience, 88-7391, Fisher Scientific Loughborough, UK), and C5b-9 (My-
BioSource, MBS703522, San Diego, CA, USA) according to the manufacturers’ instructions.
2.6. Flow Cytometry
For flow cytometry, 1 × 106 cell/mL were resuspended in PBS supplemented with
1% FBS. The cells were incubated with purified anti-Fc receptor blocking antibody (anti-
CD16/CD32 from Biolegend, San Diego, CA, UK) for 30 min in ice before staining with
saturating concentrations of antibodies specific for CD45 (APC, clone RA3-6B2; eBioscience),
CD11b (PE, clone M1/70; Ebioscience), Gr-1 (FITC, clone RB6-8C5; eBioscience), F4/80
(FITC, clone BM8, 1:250; Biolegend), or CD206 (APC, clone C068C2, 1:250; Biolegend).
Cells were washed and analysed using either CellQuest or FACSDiva 6.0 software (BD
Biosciences, San Jose, CA, USA).
2.7. Statistical Analysis
Statistical analysis was performed using GraphPad v8.0.1 (GraphPad Software) using
unpaired t-test. Serum and single cell suspensions were analysed from three independent
experiments. ELISA for CCL2, C5b-9, and C5a in sera and flow cytometry results for cell
phenotyping were performed on identical mice.
3. Results
3.1. Properdin-Deficient and Wildtype Mice Have Comparable Tumour Load
A pilot study determined subcutaneous, non-infiltrative, and non-metastasising
growth. The tumour was non-irritant and innocuous. The endpoint (diameter of tu-
mour 1 cm) was reached between 12 and 14 days. Subsequently, properdin-deficient and
congenic wildtype mice were implanted subcutaneously with the B16F10 melanoma cell
line. Tumours were measured by callipers and the volume was calculated using the formula
for ellipsoid shapes (Figure 1a). As tumours were often uneven in their circumferences,
these measurements approximated the real mass. Therefore, tumours were excised and
weighed (Figure 1b). In both cases, there was a bimodal distribution, with 3/11 tumours
being much larger than the rest and 5/14 wildtype mice clearly having large tumour
weights. Properdin-deficient mice had much less variable growth of tumour mass. Statisti-
cally, there was no difference between the groups. For in vivo assessment of the tumour
burden, we used the B16-Luc line which expresses luciferase. The tumour mass was cap-
tured by bioluminescent imaging (Figure 1c). The distribution in average radiance was
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widespread; there was no significant difference in derived tumour mass between wild type
and properdin-deficient mice. One caveat is that necrotic areas alter luminescence intensity,
so tumour mass seemed to be the more reliable measurement.
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Figure 1. Tumour burden in properdin-deficient and wildtype mice. Wildtype (PropWT) and properdin-deficient 
(PropKO) mice were injected subcutaneously with B16F10 cells. After 14 days, the tumour size was measured by callipers. 
Values are expressed as mean ± SEM from two independent experiments (a). The weight of tumours was established from 
three independent experiments (including the ones described in a) and values are expressed as mean ± SEM (b). Quanti-
tative analysis of the luciferase signal emitted from the tumour after injection of substrate 12 days following subcutaneous 
injection of B16F10-luc cells. Values are expressed as mean ± SEM from two independent experiments (c). Data were ana-
lysed by two-tailed Mann–Whitney test. 
3.2. Inflammatory Marker Expression in B16 Tumours is Altered in Properdin-Deficient Mice 
Tumours extracted from a subgroup of mice matched for the size of tumours were 
analysed quantitatively for the presence of important mediators. Of forty mediators eval-
uated, only TIMP1, IL-13, CCL2, and CCL3 were significantly different between the tu-
mour lysates prepared from the two genotypes, where properdin-deficient mice showed 
reductions in the chemoattractants CCL2, CCL3, the Th2 cytokine IL-13, and the metallo-
proteinase inhibitor TIMP-1 (Table 1 and Supplementary Figure S2). 
Table 1. Identification of genotype-discriminatory mediators by Mouse Cytokine Array in tumour 
lysates of wildtype (PropWT) and properdin-deficient (PropKO) mice. 
 PropWT (n = 3) PropKO (n = 3) p-Value 
TIMP1 45.72 ± 4.19 10.41 ± 0.91 <0.002 
IL-13 5.24 ± 1.36 0.88 ± 0.35 <0.05 
CCL2 97.49 ± 1.11 1.37 ± 0.17 <0.0001 
CCL3 46.31 ± 3.01 0.93 ± 0.41 <0.0002 
Three tumours of comparable sizes from each genotype were pooled, and extracted protein was 
analysed using Mouse Cytokine Array (R&D Systems). Reactivities were quantified densitometri-
cally. Data are expressed as means ± SD and were analysed by unpaired two-tailed t-test. 
3.3. Tumour-Bearing Properdin-Deficient Mice Have Dysregulated Systemic and Tumour Asso-
ciated Responses 
C5a, sCb-9, and CCL2 were measured at endpoint of the study (14 days) in the sera 
of tumour-bearing properdin-deficient and wildtype and were found to be significantly 
decreased in the deficient animals (Figure 2). 
Fig re . Tumour burden in pro erdin-deficient a d wildtype mic . Wildtype (Pro WT) and proper in-deficient (PropKO)
mice were injected subcutaneously with B16F10 cells. After 14 days, the tumour size was measured by callipers. Values
are expressed as mean ± SEM from two independent experiments (a). The weight of tumours was established from three
independent experiments (including the ones described in a) and values are expressed as mean ± SEM (b). Quantitative
analysis of the luciferase signal emitted from the tumour after injection of substrate 12 days following subcutaneous injection
of B16F10-luc cells. Values are expressed as mean ± SEM from two independent experiments (c). Data were analysed by
two-tailed Mann–Whitney test.
3.2. Inflammatory Marker Expression in B16 Tu ours is Altered in Properdin-Deficient Mice
Tumours extracted from a subgroup of mice matched for the size of tumours were
analysed quantitatively for the presence of important mediators. Of forty mediators
evaluated, only TIMP1, IL-13, CCL2, and CCL3 were significantly different between
the tumour lysates prepared from the two genotypes, where properdin-deficient mice
showed reductions in the chemoattractants CCL2, CCL3, the Th2 cytokine IL-13, and the
metalloproteinase inhibitor TIMP-1 (Table 1 and Supplementary Figure S2).
Table 1. Identification of genotype-discriminatory mediators by Mouse Cytokine Array in tumour
lysates of wildtype (PropWT) and properdin-deficient (PropKO) mice.
PropWT (n = 3) PropKO (n = 3) p-Value
TIMP1 45.72 ± 4.19 10.41 ± 0.91 <0.002
IL-13 5.24 ± 1.36 0.88 ± 0.35 <0.05
CL2 97.49 ± 1.11 1.37 ± 0.17 <0.0001
CCL3 46.31 ± 3.01 0.93 ± 0.41 <0.0002
Three tumours of c mparable sizes from each genot pe were pooled, and extracted protein was a alysed us ng
Mouse Cytokine Array (R&D Systems). Reactivities were quantified densitometrically. Data are expressed as
means ± SD and were analysed by unpaired two-tailed t-test.
3.3. Tumour-Bearing Properdin-Deficient Mice Have Dysregulated Systemic and Tumour
Associated Responses
C5a, sCb-9, and CCL2 were measured at endpoint of the study (14 days) in the sera
of tumour-bearing properdin-deficient and wildtype and were found to be significantly
decreased in the deficient animals (Figure 2).














































Figure 2. Serum levels of properdin- deficient (PropKO) and wildtype (PropWT) tumour-bearing mice for levels of C5a 
(a), C5b-9 (b), and CCL2 (c). Data are presented as means ± SEM. Two tailed t-tests were performed, * p < 0.05, ** p < 0.01, 
**** p < 0.0001. 
We next examined whether the reduction of these immune mediators in serum 
would mirror alterations in MDSC and M2 type macrophages of properdin-deficient mice 
from wildtype mice. Single cell suspensions were prepared from spleens and tumours of 
experimental mice 14 days after subcutaneous injection of B16F10 cells in their flanks. We 
first examined the frequency of MDSCs in the tumours of properdin-deficient and 
wildtype mice by staining with lineage-specific antibodies (Supplementary Figure S1). 
Noticeably, properdin-deficient mice had fewer MDSCs (CD45, Gr-1, and CD11b) com-
pared with wildtype mice (Figure 3a). The lower frequency of MDSCs in the tumours of 
properdin-deficient mice compared to wildtype animals was mirrored in the splenocyte 
population, where MDSCs and M2 macrophage numbers were reduced in tumour bear-
ing properdin-deficient animals. Tumour-bearing properdin wildtype mice had a higher 
number of CD206+ F4/80+ macrophages in the spleen compared with tumour-bearing pro-







Figure 3. CD45+ CD11b+ Gr-1+ population in tumours and spleens and CD206+F4/80+ population in spleens from properdin-
deficient (PropKO) and wildtype (PropWT) mice. Tumour cell suspensions were analysed for the proportion of 
CD45+ CD11b+ Gr-1+ cells (a) and splenic suspensions for the proportions of CD45+ CD11b+ Gr-1+ cells (b) and of 
CD206+F4/80+ cells (c). The data are presented as means ± SEM. Statistical analysis was performed by unpaired t-test. * p 
< 0.05, ** p < 0.01, *** p < 0.0001. 
Taken together, this study shows that, whilst properdin deficiency did not alter tu-
mour growth at 14 days post implantation, it significantly diminished inflammatory me-
diators in serum and tumours as well as immunosuppressive cell populations in the tu-
mour and the periphery. 
4. Discussion 
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4. Discussion
Using B16 F10 cell-conditioned media, we have previously described that bone
marrow-derived macrophages from properdin-deficient mice were skewed towards an M2
phenotype compared to bone marrow-derived macrophages from wildtype mice [13]. In
our in vivo model, however, properdin-deficient mice, when inoculated with logarithmi-
cally growing B16F10 cells, showed decreased levels in blood of the chemoattractants C5a
and CCL2 and in tumour of the mediators CCL2, CCL3, IL-13, and TIMP-1. There were
significantly fewer M2-skewed macrophages in the spleens of tumour-bearing properdin-
deficient mice.
We have previously described the complement system to exert measurable effects,
acting as adjuvant mediator of anti-tumour immune surveillance, adjuvant promoter
of tumour growth, and as factor in tumour immunoediting [15]. In syngeneic tumour
mouse models, the general, consistent, observation is that inhibition or blockade of com-
plement is favourable to limiting solid tumour growth over an experimental duration of
12–42 days [9,11,12,16,17].
C5a is important in the production of the chemoattractant CCL2, as in vitro and in vivo
experiments have previously shown [18,19]. The origin of elevated levels of circulating
CCL2 is likely to be tumour derived, as our study finds significantly elevated levels of
CCL2 in tumour lysates prepared from wildtype mice. CCL2 may have autocrine and
paracrine, tumour promoting, effects [20]. A mouse model of laser-induced choroidal neo-
vascularisation demonstrated that complement activation and C5b-9 formation precedes
the production of CCL2 [21]. In our study, the greater levels of C5a in tumour-bearing
wildtype mice were commensurate with elevated CCL2 levels in this group. In the presence
of properdin, complement activation has a greater turnover and produces enhanced levels
of activation (C5a) and endproducts (C5b-9) when stimulated. CCL2 has recently been
shown to be involved in tumour progression, where the genetic absence of CCL2 inhibited
recruitment of splenic myeloid-derived suppressor cells immune cells and reduced tumour
growth in a syngeneic model [22].
CCL2, CCL3, TIMP-1, and IL-13 are products readily found in an immune response
that is driven by M2 macrophages [23], which correspond to a tumour growth-promoting
phenotype that aids tumour cell proliferation, reduction of an antigen-specific immune
responses, and increased angiogenesis. M2 type macrophages have been shown to induce
the differentiation of regulatory T cells and co-determine the progression of numerous
cancers [24]. Analysis of the systemic compartment (spleen) revealed a significant reduction
of M2 type (CD206+) macrophages in tumour-bearing properdin-deficient mice compared
to wildtype mice. We propose that properdin deficiency diverted a poorly immunogenic
tumour into an “immunologically cold” one [25]. B16F10 cells do not express properdin
mRNA (own data and [3]), thus it can be concluded that suppression is due to systemically
circulating properdin rather than tumour-produced properdin. However, as complement
has a “tonic role” in cell homoeostasis [26] and complement components and receptors are
expressed by immune and non-immune cells [27], a possibility that has not been addressed
in any of the studies of syngeneic tumour models is that cell activity, in addition to cell
recruitment, may differ in the absence (targeted or genetic) of complement [28].
MDSCs, which we found elevated in the spleens and tumours of properdin wild-
type mice, can suppress anti-tumour immunity indirectly. Like M2 tumour-associated
macrophages, MDSCs generate the cytokines IL-10 and TGF-β that can suppress anti-
tumour tumour-infiltrating leukocytes, generate regulatory T cells in tumour, and convert
dendritic cells into a regulatory phenotype. MDSCs may also recruit T-regs to tumours in a
TGF-β-independent pathway [29].
We recognize that there are limitations to this work, which is largely descriptive and
employs only one C57BL/6 syngeneic model system for evaluating the effect of properdin
on tumour growth. However, our findings have important implications for the role of
properdin in modulating the tumour microenvironment, which may be important for
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therapy. A combination approach employing properdin blockade and checkpoint blockade
inhibition may be an attractive strategy and warrants further evaluation.
Taken together, our in vivo data corroborate our published in vitro data. They indicate
that properdin expression may promote an immunosuppressive tumour microenvironment
in part by increasing the expression of chemoattractants (C5a and CCL2) known to recruit
MDSCs and M2 macrophages. Combination strategies that include targeting the properdin
pathway may be useful in the immunotherapy of melanoma. It is of interest that nucleic
acid aptamers have been developed for C5a as well as CCL2 and are in clinical trials [30].
5. Conclusions
Properdin is a significant contributor to levels of C5a and CCL2 that are produced in
this murine model of melanoma and may play a role in orchestrating immunosuppressive
cells in the tumour microenvironment and periphery.
Supplementary Materials: The following are available online at https://www.mdpi.com/1010-660
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